{"id":"W2276028032","doi":"10.1007/s13300-016-0155-1","title":"A Network Meta-analysis Comparing Exenatide Once Weekly with Other GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus","year":2016,"lang":"en","type":"review","venue":"Diabetes Therapy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"ca_institutions":"Sheridan College; Public Health Ontario","funders":"AstraZeneca","keywords":"Exenatide; Medicine; Lixisenatide; Tolerability; Dulaglutide; Metformin; Liraglutide; Internal medicine; Type 2 diabetes; Glycated hemoglobin; Glucagon-like peptide 1 receptor; Discontinuation; Type 2 Diabetes Mellitus; Pharmacology; Diabetes mellitus; Adverse effect; Endocrinology; Agonist; Insulin; Receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004827387,0.001027787,0.006902353,0.0002974551,0.0001681099,0.00007770387,0.0004165078,0.0001957414,0.0005401105],"category_scores_gemma":[0.00001963047,0.0004282487,0.003826806,0.001056228,0.0002083142,0.00007098506,0.00003605945,0.0001120526,0.00005091804],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002525605,"about_ca_system_score_gemma":0.0001223445,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001528733,"about_ca_topic_score_gemma":0.00001486801,"domain_scores_codex":[0.9967387,0.0002268794,0.0009062012,0.0008026499,0.0004472191,0.0008783922],"domain_scores_gemma":[0.9954019,0.00189546,0.000917087,0.001423662,0.0002070404,0.0001548579],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00008178982,0.0005275646,0.001012529,0.001149434,0.4135447,8.480332e-7,0.00006660178,0.0000166205,0.000002200112,0.0001255579,0.0009406808,0.5825315],"study_design_scores_gemma":[0.001157904,0.002011941,0.00003259459,0.001007339,0.2780427,6.641645e-8,0.000006473443,0.00002382815,0.00005415939,0.0000349348,0.7172894,0.0003385987],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0004982382,0.9933073,0.00006741416,0.0003117786,0.0002174646,0.004975562,0.0001745078,0.000087596,0.0003601637],"genre_scores_gemma":[0.000261106,0.9898666,0.001300208,0.0002788774,0.0004175616,0.003257936,0.0004515538,0.0001841869,0.003982008],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.7163488,"threshold_uncertainty_score":0.999817,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1266099849112865,"score_gpt":0.3423086737592977,"score_spread":0.2156986888480112,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}